AzTrials
AzTrials

Heart FailureCALCICARD2NCT01956721

Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle

A study testing Exercise training, and Muscle biopsy in people with Heart Failure, run by University Hospital, Montpellier at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The aim of this project is to investigate the impact of heart failure (HF) on calcium homeostasis, mitochondrial function and oxydative stress in human skeletal muscle. The role playing by circulating factors such as cytokines and catecholamines will also be evaluated. Read more about this study

Who is it for?
Ages 35 to 65 years, men onlyHealthy volunteers can take part
Conditions the study is for
Heart Failure
What is being tested?
Exercise training, and Muscle biopsy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
22 participants
Where
1 siteFrance
Study dates
18 Sep 2013to 30 Jun 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 65 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • - BMI < 30

Who cannot join

  • Contra-indication to exercise testing performance and muscle biopsy

Trial locations and contacts

1 site in 1 country.

France1 site
  • physiologie clinique, hopital Arnaud de Villeneuve, 371 avenue du Doyen G;Giraud

    Montpellier, 34295

Other trials in France

About this study

Official title: Evaluation of Calcium Homeostasis and Mitochondrial Function in Skeletal Muscle in Subjects With Heart Failure

The aim of this project is to investigate the impact of heart failure (HF) on calcium homeostasis, mitochondrial function and oxydative stress in human skeletal muscle. The role playing by circulating factors such as cytokines and catecholamines will also be evaluated. 24 HF patients wiil be enrolled in the study: 12 male volunteers with a fraction of ejection ≥ 50% and 12 male volunteers with a fraction of ejection ≤ 35%. They will be compared to 12 sedentary healthy male volunteers, matched on age and physical activity.

Read the detailed description

Heart Failure ( HF) is associated with a skeletal muscle dysfunction, characterized by an increased fatigue that does not correlate with impaired myocardial function and physical inactivity that is commonly associated with HF. We identified in skeletal muscle of HF rats, a dysfunction of type 1 ryanodine receptors (RyR1) similar to that observed on the cardiac channel ( RyR2), due to an hyperphosphorylation of the RyR and a dissociation of the regulatory protein FKBP12. This dysfunction, in addition to mitochondrial impairment, contributes in this animal model to the reduced exercise capacity observed during HF. Our goal is to analyse the impact of HF on calcium homeostasis, mitochondrial function and oxydative stress in human skeletal muscle. This project, performed on muscle biopsies, will also allow us to correlate calcium homeostasis and mitochondrial function to circulating factors ( cytokines, catecholamines) susceptible to trigger this muscle dysfunction.This project addresses two straightforward questions about physiopathological mechanisms involved in skeletal muscle dysfunction during HF. To this aim we have built locally a network of laboratories and clinical services, used to work together, composed of two services of the University Hospital of Montpellier ( Dept. of Cardiology and Dept of Clinical Physiology), an inserm unit (U1046, team 2) all interfaced by an another Inserm facility: the Clinical Investigation center (CIC) of Montpellier. In this project we will focus on the dilated post-ischemic cardiomyopathy and compare two groups of patients under similar treatments studied at different stages of HF. The first patients with a fraction of ejection ≥ 50% will be compares with patients) with an ejection fraction ≤ 35% (12 males, 35-65 years old per HF). 12 voluntary healthy sedentary individuals carefully selected for similar level of activity as for patients will be matched to the HF groups. All individuals will undergo cardiovascular explorations (ECG and echocardiography, blood test) at the inclusion. They will perform an exercise testing to evaluate their exercise capacity. A muscle biopsy will be performed between 4 and 8 days after the exercise testing to assess the mitochondrial function and the Ca2+ homeostasis. This project will allow us to characterize the behavior of RyR in relation with mitochondrial function in human skeletal muscle during HF . The analysis of circulating factors will allow us to establish a relation of cause and effect between myocardial dysfunction and muscle dysfunction. This project could thus open important perspectives in therapeutic. Compounds analogues to JTV-519, acting in stabilizing RyR channels, could be prescribed as a potent medication for HF. This project could thus be determinant in the comprehension of the regulation of Ca2+ and energetic metabolism in human skeletal muscle which could be an appropriate model to evaluate the effects of new pharmacological agents.

Conditions
Heart Failure
Being tested
Exercise training,, Muscle biopsy
Keywords
Heart Failure , Skeletal muscle,Calcium,Ryanodine Receptor, Mitochondria, Exercise training, Muscle biopsy, Healthy volunteers
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01956721
Study groupRoleWhat they receive
Patients with heart failure (FEVG ≥ 50%)ExperimentalPatients with heart failure (FEVG ≥ 50%)
Receives: Procedure: Exercise training,; Procedure: Muscle biopsy
Patients with heart failure (FEVG ≤ 35%),ExperimentalPatients with heart failure (FEVG ≤ 35%),
Receives: Procedure: Exercise training,; Procedure: Muscle biopsy
Healthy VolunteersOtherHealthy Volunteers with no heart failure
Receives: Procedure: Exercise training,; Procedure: Muscle biopsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. calcium homeostasis

    Cell analysis

    Measured: 8 days

  2. mitochondrial function

    Cell analysis

    Measured: 8 days

Secondary outcomes (1)
  1. skeletal muscular function in two stages of heart failure

    Cell analysis

    Measured: 8 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Oct 2013 (estimated)
  2. Study start18 Sep 2013
  3. Primary completion21 Jun 2016
  4. Study completion30 Jun 2020

Why it stopped: Difficulty of inclusion

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
22 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01956721
Sponsor's protocol ID
9051
Acronym
CALCICARD2
Status last verified
Aug 2020
First submitted
12 Jun 2013
Last updated
6 Aug 2020
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise training, and Muscle biopsy in people with Heart Failure, run by University Hospital, Montpellier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 6 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Difficulty of inclusion). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

calcium homeostasis (time frame: 8 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in